SCHEMBL1850214

SCHEMBL1850214

N#Cc1sc(NC(=O)[C@H]2CCC[C@@H](C(=O)O)C2)nc1-c1cc(F)cc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 6/20 0.49
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ADORA2A P29274 5/20 0.39
ACHE P22303 3/20 0.39
KCNK2 O95069 1/20 0.39
KCNK4 Q9NYG8 1/20 0.39
ADORA1 P30542 4/20 0.38
ABL1 P00519 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPY5R Q15761 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850215 1.00 ADORA3 (0.49) ADORA3NPC1RAB9AADORA2AACHE
SCHEMBL1849219 1.00 ADORA3 (0.49) ADORA3NPC1RAB9AADORA2AACHE
SCHEMBL1848647 0.91 ADORA3 (0.54) ADORA3NPC1RAB9AADORA2AACHE
SCHEMBL1854921 0.90 ADORA3 (0.60) ADORA3ADORA2AACHEADORA1ABL1
SCHEMBL1848769 0.90 ADORA3 (0.60) ADORA3ADORA2AACHEADORA1ABL1
SCHEMBL1848774 0.90 ADORA3 (0.60) ADORA3ADORA2AACHEADORA1ABL1
SCHEMBL1854920 0.90 ADORA3 (0.60) ADORA3ADORA2AACHEADORA1ABL1
SCHEMBL1848771 0.90 ADORA3 (0.60) ADORA3ADORA2AACHEADORA1ABL1
SCHEMBL1850679 0.90 ALDH1A1 (0.48) ADORA3ADORA2AACHEKCNK2KCNK4
SCHEMBL1847573 0.90 ALDH1A1 (0.48) ADORA3ADORA2AACHEKCNK2KCNK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410282-B2 Compounds as adenosine A1 receptor antagonists PALOBIOFARMA, S.L. (ES) 2013-04-02 US disclosed
EP-2197860-B1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA SL (ES) 2011-05-25 EP disclosed
US-20100311703-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2010-12-09 US disclosed
EP-2197860-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS Palobiofarma, S.L. (ES) 2010-06-23 EP disclosed
WO-2009044250-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311703-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ADORA3 3/4885NPC1 1115/4885RAB9A 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.